Zugocabtagene geleucel

佐戈基杰仑赛

Report date: 2026/04/17 20:02:02

Base Information

Drug NameZugocabtagene geleucel
Drug Alias NameZugo-celZugocaptagene geleucelCTX-112
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursScleroderma, DiffuseScleroderma, Systemic +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesNkure Therapeutics Pvt LtdCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsSolid tumoursScleroderma, DiffuseScleroderma, Systemic +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A